Boston Scientific (BSX) Up 3.3% Since Last Earnings Report: Can It Continue?
Werte in diesem Artikel
It has been about a month since the last earnings report for Boston Scientific (BSX). Shares have added about 3.3% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Boston Scientific due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since Then?It turns out, estimates review have trended upward during the past month.VGM ScoresAt this time, Boston Scientific has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Boston Scientific has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.Performance of an Industry PlayerBoston Scientific is part of the Zacks Medical - Products industry. Over the past month, Abbott (ABT), a stock from the same industry, has gained 1.6%. The company reported its results for the quarter ended March 2025 more than a month ago.Abbott reported revenues of $10.36 billion in the last reported quarter, representing a year-over-year change of +4%. EPS of $1.09 for the same period compares with $0.98 a year ago.For the current quarter, Abbott is expected to post earnings of $1.25 per share, indicating a change of +9.7% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Abbott. Also, the stock has a VGM Score of D.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.0% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: Boston Scientific und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Boston Scientific
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Boston Scientific
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Boston Scientific Corp.
Analysen zu Boston Scientific Corp.
Datum | Rating | Analyst | |
---|---|---|---|
03.09.2019 | Boston Scientific Overweight | Barclays Capital | |
16.10.2018 | Boston Scientific Overweight | Barclays Capital | |
07.09.2018 | Boston Scientific Strong Buy | Needham & Company, LLC | |
06.07.2018 | Boston Scientific Strong Buy | Needham & Company, LLC | |
26.04.2018 | Boston Scientific Strong Buy | Needham & Company, LLC |
Datum | Rating | Analyst | |
---|---|---|---|
03.09.2019 | Boston Scientific Overweight | Barclays Capital | |
16.10.2018 | Boston Scientific Overweight | Barclays Capital | |
07.09.2018 | Boston Scientific Strong Buy | Needham & Company, LLC | |
06.07.2018 | Boston Scientific Strong Buy | Needham & Company, LLC | |
26.04.2018 | Boston Scientific Strong Buy | Needham & Company, LLC |
Datum | Rating | Analyst | |
---|---|---|---|
28.04.2016 | Boston Scientific Neutral | Wedbush Morgan Securities Inc. | |
04.05.2015 | Boston Scientific Hold | Deutsche Bank AG | |
05.02.2015 | Boston Scientific Hold | Deutsche Bank AG | |
30.09.2014 | Boston Scientific Hold | Needham & Company, LLC | |
07.01.2013 | Boston Scientific halten | Deutsche Bank Securities |
Datum | Rating | Analyst | |
---|---|---|---|
13.04.2010 | Boston Scientific "sell" | Goldman Sachs Group Inc. | |
17.03.2010 | Boston Scientific Downgrade | Goldman Sachs Group Inc. | |
10.10.2008 | Boston Scientific below average | Caris & Company, Inc. | |
02.10.2008 | Boston Scientific Downgrade | Merrill Lynch & Co., Inc. | |
13.12.2007 | Boston Scientific underperform | Friedman, Billings Ramsey & Co |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Boston Scientific Corp. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen